Regulatory approval of the Phase I-IIA study for CB-103 by Swissmedic

On October 3rd Cellestia received approval of its first-in-human Phase I – IIa clinical study with CB-103 in Switzerland.

First Investigator Meeting for CB-103-C-101

First patient dosed in first-in-human Phase l – lla clinical study with CB-103